Clinical Trial

Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity

Active, Not Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is a multicenter, randomized, partially double-blind (double-blind in both the IBI362 group and the placebo group, with the tirbopeptide group open), placebo and active drug controlled design study
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-05-30; most recent amendment 2025-12-07.
Status change: Recruiting → Active, Not Recruiting 2025-12-07
Status change: Not Yet Recruiting → Recruiting 2025-07-04
Trial Details
NCT Number NCT07000955
Lead Sponsor Innovent Biologics (Suzhou) Co. Ltd.
Conditions Obesity
Enrollment 98 participants
Start Date 2025-06-17
Primary Completion 2026-09-30 (estimated)
Study Completion 2027-05-14 (estimated)
Updated on ClinicalTrials.gov 2025-12-15